Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.

Exosomes are being considered for hair regrowth after using finasteride and minoxidil, with skepticism about their effectiveness and high cost. Users discuss administration methods like injections and microneedling, but concerns about pricing and potential scams are prevalent.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.

L'Oreal is working on hair cloning, with multiple companies using similar techniques, making hair cloning likely by 2030. The conversation expresses optimism about the progress and potential affordability of hair cloning solutions.

MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.

The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

Hair loss impacts mental health, with treatments like Minoxidil, finasteride, and stem cell transplants discussed. There is hope for future breakthroughs, but current treatments are limited, and awareness is lacking.

The user shared their positive experience with a hair transplant in South Korea, highlighting thorough consultations, consistent medical team involvement, and reasonable pricing. They noted good growth and natural-looking results after several months, with stem cell PRP treatment included to support graft survival.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

Stress can lead to hair loss by affecting hair-follicle stem cells, and this loss is harder to recover from if one has male pattern baldness (MPB). Treatments like finasteride and minoxidil are used to address hair loss, but stress-related hair loss differs from androgenic alopecia.

The user regrew their hairline using mechanical stimulation, including a 1.5mm derma roller weekly, daily scalp massages, and other treatments like Nizoral, zinc pyrithione, fish oil, and Lipogaine The Big 5. They did not use Minoxidil or finasteride.

A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.

The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.

The conversation is about organizing hair regrowth results using a standard format in a single post for easier access. Treatments mentioned include oral minoxidil, oral finasteride, and dermarolling.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.

Exosome injections stimulate hair growth by using exosomes' healing potential to awaken dormant hair follicles and promote new hair cell creation. The procedure increases scalp blood circulation, encourages collagen and elastin formation, and regenerates hair follicles, improving hair thickness and quality.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Hair regeneration and follicle cloning are considered far from being feasible, with current treatments like finasteride, minoxidil, and hair transplants expected to remain dominant for the next 15-20 years. Some are hopeful that AI advancements might accelerate progress, but many remain skeptical about significant breakthroughs in the near future.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.